ViiV Healthcare announces positive result in TANGO Phase 3 study
Category: #health  By Pankaj Singh  Date: 2019-07-11
  • share
  • Twitter
  • Facebook
  • LinkedIn

ViiV Healthcare announces positive result in TANGO Phase 3 study

ViiV Healthcare Limited, a pharmaceutical company specializing in HIV treatment, recently announced positive results from Phase 3 TANGO study.

The study was conducted to assess viral suppression in adults with HIV1 with a 2 drug regimen of dolutegravir in combination with lamivudine. Patients were chosen on the basis that they had previously maintained viral suppression for at least 6 months on a TAF (Tenofovir Alafenamide Fumarate) containing 3 drug regimens. It aimed to verify whether the same could be achieved through the 2 drug regimen. The results from the study will be presented at the 10th IAS Conference on HIV Science, in Mexico City.

Based on a proportion of participants with plasma HIV 1 RNA≥50 copies c/ml, using the Food & Drug Administration Snapshot algorithm at 48th week, the study has reportedly reached its primary end-point for non-inferiority. None of the patients developed treatment resistance in the dolutegravir and lamivudine arm of the study nor did they meet confirmed virologic withdrawal criteria. The safety results for the 2 drug regimen of dolutegravir in combination with lamivudine were consistent with the product labelling for the medicines.

Kimberly Smith, MD and Head of Global Research & Medical Strategy at ViiV Healthcare Limited, was reportedly quoted saying that the company has been developing the TANGO study to reduce the number of medicines in HIV treatment regimen to maintain viral suppression. The 48th week data from the final study proves that patients, who are already on treatment can maintain viral suppression if they switch from a 3 drug tenofovir alafenamide fumarate -containing regimen to a 2 drug regimen of dolutegravir in combination with lamivudine.

As per credible sources, the single-pill, 2-drug dolutegravir in combination with lamivudine, was authorized in U.S. earlier this year for the treatment of HIV-1 infection in adults with no ARV (antiretroviral) treatment history & with no known resistance to either lamivudine or dolutegravir. It was also authorized in Europe recently for the treatment of HIV 1 infection in adults & adolescents above 12 years, with minimum weight of 40 kg, with no known or suspected resistance to the INI (integrase inhibitor) class, or lamivudine.

Source credit: https://www.viivhealthcare.com/en-gb/media/press-releases/2019/july/viiv-healthcare-announces-phase-iii-study-meets-primary-endpoint/



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...